Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmv Capital Regulatory News (EMVC)

Share Price Information for Emv Capital (EMVC)

Share Price is delayed by 15 minutes
Get Live Data
49.00    0.00 (0.00%)
Bid:
48.00
Ask:
50.00
Spread: 2.00 (4.167%)
Market Cap: £13.70m
EMVC Live PriceLast checked at - London Stock Exchange

Intraday Emv Capital Share Chart

TR-1

10 Jun 2025 13:28

RNS Number : 2458M
EMV Capital PLC
10 June 2025
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BN4R5Q82

Issuer Name EMV CAPITAL PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

James Robert Kight

City of registered office (if applicable)

Hale

Country of registered office (if applicable)

England

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

10-June-2025

6. Date on which Issuer notified

10-June-2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.11742

0.000000

5.11742

1,400,000

Position of previous notification (if applicable)

4.11221

0.000000

4.11221

1,125,000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BN4R5Q82

1,400,000

5.11742

Sub Total 8.A

1,400,000

5.11742

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

10-June-2025

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAAKEFASSEFA
12
Date   Source Headline
22nd May 202612:38 pmRNSPosting of Annual Report and Notice of AGM
21st May 20267:00 amRNS-RAMR Bio: Commercial Update
19th May 20267:01 amRNSFinal Results for the year ended 31 December 2025
19th May 20267:00 amRNSPhantom Carried Interest Scheme
14th May 20267:00 amRNSNotice of Final Results
24th Feb 202612:38 pmRNSTR-1
12th Feb 20267:00 amRNS-RPortfolio Update
2nd Feb 20267:00 amRNSTrading and Portfolio Update
8th Jan 20267:00 amRNSPDMR Dealing
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
19th Dec 20257:00 amRNSDirector/PDMR Dealing
19th Dec 20257:00 amRNSDirector/PDMR Dealing
10th Dec 20257:00 amRNS-RWanda Health: Fundraising and Business Update
8th Dec 20257:00 amRNSShare Issue, PDMR Dealings & Total Voting Rights
4th Dec 20257:00 amRNSTR-1
24th Nov 20257:00 amRNSExpansion of Senior Finance Leadership Team
20th Nov 20257:00 amRNS-RPortfolio Update
30th Sep 20257:00 amRNSInterim Results and Investor Presentation
22nd Sep 20257:00 amRNSAsset Purchase Agreement with Destiny Pharma
18th Sep 20257:00 amRNSNotice of Interim Results
30th Jun 202512:22 pmRNSResult of AGM
30th Jun 20257:00 amRNSOffice move and Related Party Transaction
27th Jun 20257:00 amRNSQ-Bot Limited Fundraising
10th Jun 20251:28 pmRNSTR-1
6th Jun 20253:12 pmRNSNotice of AGM and Annual Report & Accounts
4th Jun 20252:34 pmRNSDirector/PDMR Shareholding
4th Jun 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
14th May 20254:02 pmRNSPDS: Q1 Results and Clinical and Corporate Update
9th May 202510:30 amRNSTR-1
27th Mar 20254:46 pmRNSPDS: Q4 Results and Clinical Programs Update
7th Mar 20254:26 pmRNSPDS: VERSATILE-003 Phase 3 Clinical Trial
27th Feb 20254:30 pmRNSPDS: up to $22mn Registered Direct Offering
5th Feb 20253:24 pmRNSPDS Biotech reaffirms guidance for clinical trial
3rd Feb 20257:00 amRNSProAxsis: Status Update and Proposed Fundraise
6th Jan 20254:42 pmRNSTR-1
31st Dec 20247:05 amRNSGrant of Share Options
31st Dec 20247:00 amRNSQ-Bot Fundraising
12th Dec 20244:49 pmRNSTR-1
9th Dec 20247:00 amRNSWanda Health Fundraising
5th Dec 20247:00 amRNSClose of Fundraising and Result of Retail Offer
3rd Dec 20241:24 pmRNSResult of Subscription
3rd Dec 20247:05 amRNSWRAP Retail Offer
3rd Dec 20247:00 amRNSProposed Subscription and Retail Offer; Update
14th Nov 20243:59 pmRNSReplacement RNS: PDS: Update, 3rd Quarter Results
14th Nov 20243:23 pmRNSPDS: Clinical Programs Update, 3rd Quarter Results
8th Oct 20247:00 amRNSDirector/PDMR Shareholding
3rd Oct 20247:00 amRNSDirector/PDMR Shareholding
2nd Oct 20244:38 pmRNSPDS: 36-Month Overall Survival Rate announcement
30th Sep 20247:00 amRNSInterim Results
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.